GGrantIndex
Sort

40,608 grants matching prostate cancer

THE (CPCA): A COOPERATIVE EFFORT FOR CONDUCTING PROSTATE CANCER-FOCUSED CLINICAL TRIALS

$1,255,244
University Of Chicago · · FY2009 · Department of Defense

Multi Source E-Beam kV X-Ray Tube for Image-Guided Radiotheraphy

$1,254,926
Douglas P Boyd · Telesecurity Sciences, Inc. · R44 · FY2016 · CA

Center for Interventional Oncology

$1,254,568
Bradford J Wood · Division Of Basic Sciences - Nci · ZID · FY2022 · CA

An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)

$1,254,180
Dennis Brown · Kintara Therapeutics, Inc. · R44 · FY2023 · CA

Loma Linda University Center for Health Disparities Research

$1,253,971
Marino De Leon · Loma Linda University · P20 · FY2014 · MD

NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER

$1,253,944
New York University School Of Medicine · U01 · FY2002 · CA

Nutrition, Metabolism, and Cancer

$1,252,965
Regina G Ziegler · Cancer Epidemiology And Genetics · Z01 · FY2007 · CA

STRUCTURE FUNCTION AND INHIBITION OF ONECUT2, DRIVER OF PROSTATE CANCER

$1,252,500
Cedars-Sinai Medical Center · · FY2025 · Defense Health Agency

RIPK2 AS A THERAPEUTIC TARGET IN ADVANCED PROSTATE CANCERS

$1,252,500
The Research Foundation For The State University Of New York · · FY2022 · Defense Health Agency

MECHANISMS AND THERAPEUTIC TARGETING OF NUCLEAR SHAPE INSTABILITY IN LETHAL PROSTATE CANCER

$1,252,500
Cedars-Sinai Medical Center · · FY2020 · Defense Health Agency

DRIVERS AND DOWNSTREAM EFFECTORS OF WNT SIGNALING IN LETHAL PROSTATE CANCER

$1,252,396
Beth Israel Deaconess Medical Center, Inc. · · FY2020 · Defense Health Agency

NOVEL LINEAGE PLASTICITY INHIBITORS IN PROSTATE CANCER

$1,252,233
Cedars-Sinai Medical Center · · FY2022 · Department of the Army

Comprhensive Center of Excellence in Health Disparities

$1,251,750
Timothy R Rebbeck · University Of Pennsylvania · P60 · FY2013 · MD

AN IMMUNOTHERANOSTIC ANTIBODY FOR THE DETECTION AND ERADICATION OF METASTATIC PROSTATE CANCER: A PROOF-OF-CONCEPT STUDY IN NONHUMAN PRIMATES

$1,250,847
Sloan-Kettering Institute For Cancer Research · · FY2018 · Defense Health Agency

Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial

$1,250,136
Lance Yokochi · Pacific Health Research/ Education Inst · N01 · FY2010 · CA

TARGETING ONCOGENOMIC FUNCTION OF N-MYC TO INHIBIT NEUROENDOCRINE PROSTATE CANCER VISCERAL METASTASIS

$1,250,131
Duke University · · FY2025 · Defense Health Agency

PROSTATE CANCER CLINICAL TRIALS CONSORTIUM: JOHNS HOPKINS KIMMEL CENCER CENTER SITE

$1,250,015
The Johns Hopkins University · · FY2009 · Department of the Army

SPORE IN PROSTATE CANCER

$1,250,001
University Of Michigan At Ann Arbor · P50 · FY2002 · CA

Clinical and Translational Science Award

$1,250,000
Reza Shaker · Medical College Of Wisconsin · UL1 · FY2021 · TR

Regional Oncology Research Center

$1,250,000
Martin D Abeloff · Johns Hopkins University · P30 · FY2006 · CA

LOW-DOSE RADIATION EX VIVO REPROGRAMMED/ACTIVATED CAR T CELLS TARGETING B7-H3 ON PROSTATE CANCER.

$1,249,800
The General Hospital Corporation · · FY2021 · Defense Health Agency

Comparative Analysis of Cancer-Associated Genes and Development of a Gene Delive

$1,249,380
Vladimir Larionov · Basic Sciences · Z01 · FY2007 · CA

Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study

$1,249,143
Demetrius Albanes · Division Of Cancer Epidemiology And Genetics · ZIA · FY2015 · CA

IMPROVING OUTCOMES IN LETHAL PROSTATE CANCER THROUGH GUIDELINE-CONCORDANT USE OF BONE-MODIFYING AGENTS

$1,248,613
Sloan-Kettering Institute For Cancer Research · · FY2021 · Defense Health Agency

Metal Chelate Conjugated Monoclonal Antibodies for Tumor Diagnosis and Therapy

$1,247,747
Martin W Brechbiel · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA